Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT

Donal P. McLornan, Richard Szydlo, Marie Robin, Anja van Biezen, Linda Koster, Henrik J.P. Blok, Maria T. Van Lint, Jürgen Finke, Antonin Vitek, Kristina Carlson, Laimonas Griskevicius, Ernst Holler, Maija Itälä-Remes, Michel Schaap, Gerard Socié, Jacques Olivier Bay, Yves Beguin, Benedetto Bruno, Jan J. Cornelissen, Tobias Gedde-DahlPer Ljungman, Marie T. Rubio, Ibrahim Yakoub-Agha, Evgeny Klyuchnikov, Eduardo Olavarria, Yves Chalandon, Nicolaus Kröger

Research output: Contribution to journalArticlepeer-review

Abstract

Allogeneic Haematopoietic Stem Cell Transplant (allo-HSCT) remains the only curative approach for Myelofibrosis (MF). Scarce information exists in the literature on the outcome and, indeed, management of those MF patients who relapse following transplant. We hereby report on the management and outcome of 202 patients who relapsed post allo-HSCT for MF.

Original languageEnglish
Pages (from-to)418-422
Number of pages5
JournalBritish Journal of Haematology
Volume182
Issue number3
DOIs
Publication statusPublished - Aug 1 2018

Keywords

  • allogeneic stem cell transplant
  • fibrosis
  • JAK inhibitors
  • mylelofibrosis
  • relapse

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT'. Together they form a unique fingerprint.

Cite this